2024

1. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

   Lung Cancer, Vol. 194

2. Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial

   British Journal of Cancer, Vol. 130, Núm. 3, pp. 417-424